Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.

China’s NMPA approves Eylea 8 mg for wet age-related macular degeneration: Berlin Friday, May 23, 2025, 09:00 Hrs [IST] The Center for Drug Evaluation (CDE) of China’s Nationa ...

Intraocular inflammation occurred more frequently with 8-mg aflibercept (Eylea) compared with what was observed in previous clinical trials among patients with neovascular age-related macular ...

Aflibercept 8 mg demonstrated sustained functional and anatomic improvements in patients with wet age-related macular degeneration through 156 weeks, according to a presenter.

At ARVO 2025, in Salt Lake City, Utah, Ferhina Ali, MD, MPH, talked about her presentation on the early real-world use of aflibercept 8 mg in treatment-naive patients with neovascular age-related macu ...

Patients with diabetic macular edema treated with intravitreal aflibercept have a significantly higher risk of adverse renal events compared with those treated with ranibizumab.

This trial demonstrated that aflibercept on a PRN basis maintained visual gains achieved in the first 6 months of treatment over a period of 18 months. [46] The data also demonstrated the efficacy ...

EYLEA HD ® (aflibercept) Injection 8 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), and ...

The analysis included 41 patients who were treated with 136 intravitreal aflibercept, 8mg, injections. HealthDay News — The incidence of mild intraocular inflammation (IOI) in the real world ...

EYLEA HD® (aflibercept) Injection 8 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), and ...

UBX1325 treatment led to visual acuity gains of over 5 letters from baseline at weeks 24 and 36, and achieved non-inferiority to aflibercept at 9 out of 10 time points through 36 weeks ...

Among 41 patients treated with 8-mg aflibercept, five developed mild sterile intraocular inflammation within 1 to 3 days. All cases resolved with treatment and caused no permanent vision loss.